Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Novartis AG (NVS) Price & Performance

Cytokinetics IncTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Novartis AG — how do they compare? Cytokinetics Inc trades at $77.39 (market cap $10.63B), while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG is far larger — about 27.8× Cytokinetics Inc's market cap, and Novartis AG pays a 3.07% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKNVS
Market Cap
$10.63B$295.37B
Sector
TechnologyHealth
52-Week High
$87.26$168.62
52-Week Low
$34.31$119.31
Enterprise Value
$10.74B$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.

The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.

Novartis AG

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS